New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
08:24 EDTTKMRTekmira Ebola drug could see emergency use in U.S., says Maxim
Maxim said the FDA's decision to change its full clinical hold on TKM-Ebola to a partial hold paves the way for potential emergency use of the drug in the U.S., if needed. Maxim noted that Tekmira's DOD contract for development of the treatment is initially worth $140M, adding that the firm expect Tekmira to receive a government supplier contract by 2018 for the drug. Maxim keeps its Buy rating and $23 price target on the stock.
News For TKMR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
10:00 EDTTKMROn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:15 EDTTKMRTekmira initiated with a Buy at Nomura
Target $32.
March 25, 2015
19:34 EDTTKMRTekmira 'encouraged' by new preclinical data on TKM-HTG
Subscribe for More Information
March 20, 2015
06:17 EDTTKMRTekmira 7.5M share Secondary priced at $20.25
Subscribe for More Information
March 19, 2015
09:20 EDTTKMROn The Fly: Pre-market Movers
Subscribe for More Information
March 18, 2015
18:32 EDTTKMROn The Fly: After Hours Movers
UP AFTER EARNINGS: Guess (GES), up 12.4% after reporting fourth quarter results and guidance... Shoe Carnival (SCVL), up 10%... NQ Mobile (NQ), up 9.1%... Tilly's (TLYS), up 1.3%... Cintas (CTAS), up 1.3% after reporting quarterly results and raising fiscal 2015 guidance. DOWN AFTER EARNINGS: Williams-Sonoma (WSM), down 4.1%... Jabil Circuit (JBL), down 1.8%... Juno Therapeutics (JUNO), down 3.3%. ALSO LOWER: Concert Pharmaceuticals (CNCE), down 4.4% after filing to sell common stock... Tekmira Pharmaceuticals (TKMR), down 3.7% after filing to sell 6M shares of common stock.
16:19 EDTTKMRTekmira files to sell 6M shares of common stock
Leerink Partners LLC and RBC Capital Markets LLC are acting as joint lead book-runners for the offering. Nomura is acting as a book-runner for the offering. Co-managers for the offering are: JMP Securities, Wedbush PacGrow Life Sciences and Lazard Frères & Co.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use